Identification of biomarkers of immune checkpoint blockade efficacy in recurrent or refractory solid tumor malignancies.

Patients with high TMB (>12 reported mutations), however, showed a trend towards improved survival when treated with ICB (HR = 0.586, 95% CI [0.275–1.246]) ( Figure 3C and 3D ) ( p = 0.0035 Log-rank (Mantel-Cox) test, p = 0.211 Log rank test for trend).

also in 53,322 other papers

Interestingly, the improvement in hazard ratio of patients without a tumor mutant DR gene when treated on ICB was less than that seen in patients with tumors with mutated DR genes when treated with ICB was (HR = 0.564 95%CI [0.446 to 0.712], n = 91 vs n = 340, p<0.0001), though still highly significant.

also in 132,142 other papers